SCHEMBL896853

SCHEMBL896853

CC(C)(C)OC(=O)CN(CC(=O)OC(C)(C)C)[C@@H](CCCCN)C(=O)OC(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
CPB2 Q96IY4 6/20 0.37
EPOR P19235 2/20 0.36
GSR P00390 1/20 0.32
RNPEP Q9H4A4 1/20 0.31
CYP1A2 P05177 1/20 0.31
CTSK P43235 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4537445 1.00 CPB2 (0.37) CPB2EPORGSRRNPEPCYP1A2
SCHEMBL7601678 0.90 CPB2 (0.33) CPB2EPOR
SCHEMBL5543850 0.88 CPB2 (0.33) CPB2EPOR
SCHEMBL2567911 0.88 CPB2 (0.33) CPB2EPOR
SCHEMBL22966171 0.87 TDP1 (0.37) CTSK
SCHEMBL18291030 0.85 GNAI3 (0.37) EPOR
SCHEMBL19765214 0.83 EPOR (0.31) EPOR
SCHEMBL6232124 0.82 EPOR (0.40) CPB2EPOR
SCHEMBL15215664 0.81 KDM4E (0.39)
SCHEMBL6232568 0.80 EPOR (0.40) CPB2EPORCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180346606-A1 REVERSIBLE PROTEIN MULTIMERS, METHODS FOR THEIR PRODUCTION AND USE LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (US) 2018-12-06 US disclosed
US-10023657-B2 Reversible protein multimers, methods for their production and use LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (US) 2018-07-17 US disclosed
US-9606114-B2 Multivalent chelators containing a scaffold structure for modifying and organizing of target molecules JOHANN WOLFGANG GOETHE-UNIVERSITAT FRANKFURT AM MAIN (DE) 2017-03-28 US disclosed
US-20130289253-A1 REVERSIBLE PROTEIN MULTIMERS, METHODS FOR THEIR PRODUCTION AND USE LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (US) 2013-10-31 US disclosed
EP-1778651-B1 MULTIVALENT CHELATORS FOR MODIFYING AND ORGANIZING OF TARGET MOLECULES UNIV JW GOETHE FRANKFURT MAIN (DE) 2013-09-04 EP disclosed
US-8198230-B2 Synthetic mimics of mammalian cell surface receptors: method and compositions THE PENN STATE RESEARCH FOUNDATION (US) 2012-06-12 US disclosed
WO-2012044999-A2 REVERSIBLE PROTEIN MULTIMERS, METHODS FOR THEIR PRODUCTION AND USE LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (US) 2012-04-05 WO disclosed
US-20110236344-A1 Synthetic mimics of mammalian cell surface receptors: method and compositions THE PENN STATE RESEARCH FOUNDATION (US) 2011-09-29 US disclosed
WO-2011101445-A1 HIGH-AFFINITY MULTIVALENT CHELATOR COMPOUNDS (MCHS) AND THEIR USE FOR THE STRUCTURAL AND FUNCTIONAL ANALYSIS OF TARGET MOLECULES Johann Wolfgang Goethe-Universität Frankfurt am Main (DE) 2011-08-25 WO disclosed
US-7956029-B2 Synthetic mimics of mammalian cell surface receptors: method and compositions THE PENN STATE RESEARCH FOUNDATION (US) 2011-06-07 US disclosed
US-7947647-B2 Synthetic mimics of mammalian cell surface receptors: method and compositions THE PENN STATE RESEARCH FOUNDATION (US) 2011-05-24 US disclosed
US-20100160657-A1 SYNTHETIC MIMICS OF MAMMALIAN CELL SURFACE RECEPTORS: METHOD AND COMPOSITIONS THE PENN STATE RESEARCH FOUNDATION (US) 2010-06-24 US disclosed
US-20100029906-A1 Synthetic mimics of mammalian cell surface receptors: method and compositions THE PENN STATE RESEARCH FOUNDATION (US) 2010-02-04 US disclosed
US-20090197848-A1 Synthetic mimics of mammalian cell surface receptors: method and compositions THE PENN STATE RESEARCH FOUNDATION (US) 2009-08-06 US disclosed
US-7514400-B2 Synthetic mimics of mammalian cell surface receptors: method and compositions THE PENN STATE RESEARCH FOUNDATION (US) 2009-04-07 US disclosed
US-20080038750-A1 Multivalent Chelators for Modifying and Organizing of Target Molecules JOHANN WOLFGANG GOETHE-UNIVERSITAT FRANKFURT AM MAIN (DE) 2008-02-14 US disclosed
US-20060229235-A1 Synthetic mimics of mammalian cell surface receptors: method and compositions THE PENN STATE RESEARCH FOUNDATION (US) 2006-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180346606-A1 REVERSIBLE PROTEIN MULTIMERS, METHODS FOR THEIR PRODUCTION AND USE CD4, CD74, CD69 CPB2 1981/4885EPOR 518/4885GSR 1254/4885
US-20100160657-A1 SYNTHETIC MIMICS OF MAMMALIAN CELL SURFACE RECEPTORS: METHOD AND COMPOSITIONS NR1H4, LDLR, NR1H3 CPB2 1622/4885EPOR 316/4885GSR 3575/4885
US-20090197848-A1 Synthetic mimics of mammalian cell surface receptors: method and compositions MSR1, M6PR, ASGR1 CPB2 1105/4885EPOR 155/4885GSR 3341/4885
US-20080038750-A1 Multivalent Chelators for Modifying and Organizing of Target Molecules GLMN, SPEN, LGMN CPB2 2090/4885EPOR 1529/4885GSR 2695/4885
US-20130289253-A1 REVERSIBLE PROTEIN MULTIMERS, METHODS FOR THEIR PRODUCTION AND USE CD4, CD74, CD69 CPB2 1981/4885EPOR 518/4885GSR 1254/4885
US-20060229235-A1 Synthetic mimics of mammalian cell surface receptors: method and compositions MSR1, M6PR, ASGR1 CPB2 1105/4885EPOR 155/4885GSR 3341/4885
US-20100029906-A1 Synthetic mimics of mammalian cell surface receptors: method and compositions MSR1, M6PR, ASGR1 CPB2 1105/4885EPOR 155/4885GSR 3341/4885
US-20110236344-A1 Synthetic mimics of mammalian cell surface receptors: method and compositions MSR1, M6PR, ASGR1 CPB2 1105/4885EPOR 155/4885GSR 3341/4885
US-10023657-B2 Reversible protein multimers, methods for their production and use CD4, CD74, CD69 CPB2 1981/4885EPOR 518/4885GSR 1254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.